Does MOGAMULIZUMAB-KPKC Cause Therapy partial responder? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Therapy partial responder have been filed in association with MOGAMULIZUMAB-KPKC. This represents 1.2% of all adverse event reports for MOGAMULIZUMAB-KPKC.
14
Reports of Therapy partial responder with MOGAMULIZUMAB-KPKC
1.2%
of all MOGAMULIZUMAB-KPKC reports
1
Deaths
1
Hospitalizations
How Dangerous Is Therapy partial responder From MOGAMULIZUMAB-KPKC?
Of the 14 reports, 1 (7.1%) resulted in death, 1 (7.1%) required hospitalization.
Is Therapy partial responder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MOGAMULIZUMAB-KPKC. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does MOGAMULIZUMAB-KPKC Cause?
Rash (177)
Disease progression (107)
Drug eruption (62)
Pruritus (58)
Infusion related reaction (54)
Death (45)
Fatigue (44)
Chills (40)
Inappropriate schedule of product administration (39)
Pyrexia (39)
What Other Drugs Cause Therapy partial responder?
CYCLOPHOSPHAMIDE (1,397)
RITUXIMAB (1,219)
DEXAMETHASONE (1,199)
PREDNISONE (1,176)
PEMBROLIZUMAB (1,125)
CARBOPLATIN (1,096)
DOXORUBICIN (834)
METHOTREXATE (775)
VINCRISTINE (707)
ETOPOSIDE (670)
Which MOGAMULIZUMAB-KPKC Alternatives Have Lower Therapy partial responder Risk?
MOGAMULIZUMAB-KPKC vs MOLNUPIRAVIR
MOGAMULIZUMAB-KPKC vs MOLSIDOMINE
MOGAMULIZUMAB-KPKC vs MOMELOTINIB
MOGAMULIZUMAB-KPKC vs MOMETASONE
MOGAMULIZUMAB-KPKC vs MOMETASONE FUROATE